These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 27628794)

  • 21. Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.
    Beltran H; Antonarakis ES; Morris MJ; Attard G
    Am Soc Clin Oncol Educ Book; 2016; 35():131-41. PubMed ID: 27249694
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Rebello RJ; Oing C; Gillessen S; Bristow RG
    Clin Cancer Res; 2019 Mar; 25(6):1699-1701. PubMed ID: 30610102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3.
    Steinestel J; Bernemann C; Schrader AJ; Lennerz JK
    Eur Urol; 2017 Apr; 71(4):e107-e108. PubMed ID: 27647434
    [No Abstract]   [Full Text] [Related]  

  • 24. A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.
    García JL; Lozano R; Misiewicz-Krzeminska I; Fernández-Mateos J; Krzeminski P; Alfonso S; Marcos RA; García R; Gómez-Veiga F; Virseda Á; Herrero M; Olmos D; Cruz-Hernández JJ
    Clin Transl Oncol; 2017 Nov; 19(11):1350-1357. PubMed ID: 28600675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [AR-V7 as a predictive biomarker for prostate cancer-more than just prophecy].
    Bernemann C; Krabbe LM
    Urologe A; 2020 Jan; 59(1):80-83. PubMed ID: 31820021
    [No Abstract]   [Full Text] [Related]  

  • 27. Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail.
    Plymate SR; Sharp A; de Bono JS
    JAMA Oncol; 2018 Sep; 4(9):1187-1188. PubMed ID: 29955776
    [No Abstract]   [Full Text] [Related]  

  • 28. Has the PROPHECY of AR-V7 Been Fulfilled?
    De Laere B; Ost P; Grönberg H; Lindberg J
    J Clin Oncol; 2019 Aug; 37(24):2181-2182. PubMed ID: 31265360
    [No Abstract]   [Full Text] [Related]  

  • 29. Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer.
    Sharp A; Porta N; Lambros MBK; Welti JC; Paschalis A; Raj GV; Plymate SP; de Bono JS
    J Clin Oncol; 2019 Aug; 37(24):2182-2184. PubMed ID: 31265359
    [No Abstract]   [Full Text] [Related]  

  • 30. Re: ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
    Atala A
    J Urol; 2019 Nov; 202(5):869-870. PubMed ID: 31365309
    [No Abstract]   [Full Text] [Related]  

  • 31. Novel AR-V7 detection in whole blood samples in patients with prostate cancer: not as simple as it seems.
    Bernemann C; Steinestel J; Boegemann M; Schrader AJ
    World J Urol; 2017 Oct; 35(10):1625-1627. PubMed ID: 28243791
    [No Abstract]   [Full Text] [Related]  

  • 32. AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification.
    Sowalsky AG; Sharp A; Trostel SY; de Bono JS; Plymate SR
    Cancer Treat Res Commun; 2021; 28():100218. PubMed ID: 33516656
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical Acumen Versus Androgen Receptor Variant 7 Circulating Tumor Cells in Decision-Making for Men with Advanced Prostate Cancer.
    Montgomery B; Plymate S
    Eur Urol; 2020 Feb; 77(2):178-179. PubMed ID: 31615710
    [No Abstract]   [Full Text] [Related]  

  • 34. Practical Polling for Prostate Cancer: AR-V7-based Treatment Selection.
    Lamb AD; Lawrence MG; Sandhu S
    Eur Urol; 2017 Jun; 71(6):883-885. PubMed ID: 28089303
    [No Abstract]   [Full Text] [Related]  

  • 35. Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? - Authors' reply.
    Clarke N
    Lancet Oncol; 2018 Sep; 19(9):e438. PubMed ID: 30191845
    [No Abstract]   [Full Text] [Related]  

  • 36. Predictive Significance of Androgen Receptor Splice Variant 7 in Patients With Metastatic Castration-Resistant Prostate Cancer: The PROPHECY Study.
    Dirix L
    J Clin Oncol; 2019 Aug; 37(24):2180-2181. PubMed ID: 31265358
    [No Abstract]   [Full Text] [Related]  

  • 37. AR-Variant-Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?
    Dehm SM; Montgomery B; Plymate SR
    Clin Cancer Res; 2019 Mar; 25(6):1696-1698. PubMed ID: 30591516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen?
    Ren C; Han C; Wang D; Chen H
    J Clin Oncol; 2018 Aug; 36(22):2353-2354. PubMed ID: 29894275
    [No Abstract]   [Full Text] [Related]  

  • 39. The way towards understanding possible multiple functions of AR V7 in prostate cancer.
    Culig Z
    BJU Int; 2018 Aug; 122(2):169. PubMed ID: 30134059
    [No Abstract]   [Full Text] [Related]  

  • 40. Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test.
    Nicolazzo C; Gradilone A; Gazzaniga P
    JAMA Oncol; 2019 Mar; 5(3):433-434. PubMed ID: 30703189
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.